***Background.*** Invasive pneumococcal infections (IPI) due to *Streptococcus pneumoniae* serotype (ST) 3 have not declined as dramatically in children as other vaccine STs since the introduction in 2010 of the 13-valent pneumococcal conjugate vaccine, PCV13. While persistence of ST 3 isolates is likely due to capsule characteristics, genotypes with greater fitness may also emerge. We analyzed molecular characteristics of *S. pneumoniae* ST 3 isolates that were obtained from children with IPI.

***Methods.*** IPI cases at 8 children\'s hospitals in the United States were prospectively identified from 2008-2013. ST 3 isolates were selected from the associated database. Isolates were typed by multilocus sequence typing (MLST). Select patient information was analyzed and antibiotic susceptibility patterns were compared. Statistical analysis included Wilcoxon rank-sum and Fisher\'s exact tests.

***Results.*** Sixty-three patients with 62 isolates were identified from the database (Table); 36 were male. Median age was 3.7y (0.1-17.6y). Disease presentations were pneumonia (n = 33), meningitis (n = 9), bacteremia (n = 7), mastoiditis (n = 6), cellulitis/abscess (n = 7), and peritonitis (n = 1). Twelve (19%) patients had an underlying condition. The MLSTs were 180 (n = 58), 260, 338, 433 and 1116. The MLST distribution did not change over time. All isolates were penicillin and ceftriaxone susceptible. Only 3 were resistant to erythromycin and 2 were resistant to clindamycin.

###### 

Characteristics of pediatric serotype 3 infections, 2008-2013

  Year    Total invasive SPN   Serotype 3 (% of total)   MLST 180   Pneumonia (% of total serotype 3)   Mean Age (years)
  ------- -------------------- ------------------------- ---------- ----------------------------------- ------------------
  2008    197                  11 (6%)                   11         8 (73%)                             3.1
  2009    219                  22 (10%)                  20         7 (32%)                             5.6
  2010    165                  8 (5%)                    7          5 (63%)                             3.4
  2011    128                  5 (4%)                    4          1 (20%)                             6.2
  2012    112                  6 (5%)                    5          4 (67%)                             5.7
  2013    104                  11 (11%)                  11         8 (73%)                             6.2
  Total   925                  63                        58         33                                  5.0

***Conclusion.*** ST 3 isolates chiefly caused pneumonia in this patient population and were mainly MLST180. MLST distribution did not change following introduction of PCV13. No statistical differences in distribution, age, disease presentation, age or, antibiotic susceptibility were observed. A modified vaccine, potentially including non-capsular antigens, is likely required to optimally reduce IPI due to ST 3 in children.

***Disclosures.*** **S. L. Kaplan**, Pfizer: Grant Investigator and Scientific Advisor, Consulting fee and Grant recipient **W. J. Barson**, UpToDate: Author, Royalty; Pfizer: Investigator, Research support; Wyeth: Investigator, Research support **T. Tan**, Pfizer/Wyeth: Scientific Advisor **L. B. Givner**, Pfizer: Investigator, Research support

[^1]: **Session:** 116. Pediatric - Bacterial Studies

[^2]: Friday, October 10, 2014: 12:30 PM
